1. A multi-centre double blind randomized study to compare the safety and efficacy of once-daily ORG 10172 and twice-daily low-dose heparin in preventing deep-vein thrombosis in patients with acute ischaemic stroke;Dumas;Age and Ageing,1994
2. Hageluken C Egberts J Stiekema J A multi-centre, assessor-blind, randomised, safety study of Org 10172, administered subcutaneously twice daily, for the prophylaxis of deep vein thrombosis in patients with a non-haemorrhagic stroke of recent onset (protocol 87038) Organon International B.V. (Internal report SDGRR No. 3165), Oss, The Netherlands 1992
3. Hageluken C Egberts J A multi-centre, assessor-blind, randomised pilot study of three different doses of Org 10172 (375, 750 and 1250U), administered subcutaneously once daily, compared with low dose heparin, administered subcutaneously twice daily, in the prophylaxis of deep vein thrombosis (DVT) in patients with a non-haemorrhagic stroke of recent onset (protocol 85144) Organon International B.V. (Internal report SDGRR No. 3158). Oss, the Netherlands 1992
4. Enoxaparin, a low-molecular-weight heparin (LWMH) may be superior to standard heparin in the prevention of deep-vein thrombosis (DVT) in stroke patients;Hillbom;European Journal of Neurology,1998
5. Hillbom M Erila T Flosbach CW Sotaniemi K Sarna S Kaste M Enoxaparin, a low molecular weight heparin, is superior to heparin in the prevention of deep vein thrombosis in patients with acute atherosclerotic stroke Proceedings of the 17th Congress of the International Society on Thrombosis and Haemostasis; 1999 August 14-21; Washington, DC, USA 1999